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The cholesteryl ester transfer protein (CETP) enables the transfer of cholesteryl ester (CE) from high-
density lipoproteins (HDL) to low-density lipoproteins (LDL) in the plasma compartment. CETP inhibition
raises plasma levels of HDL cholesterol; a ternary tunnel complex with CETP bridging HDL and LDL was
suggested as a mechanism. Here, we test whether the inhibition of CETP tunnel complex formation is a
promising approach to suppress CE transfer from HDL to LDL, for potential treatment of cardio-vascular
disease (CVD). Three monoclonal antibodies against different epitopes of CETP are assayed for their
potential to interfere with CE transfer between HDL and/or LDL. Surprisingly, antibodies that target the
tips of the elongated CETP molecule, interaction sites sterically required to form the suggested transfer
complexes, do not interfere with CETP activity, but an antibody binding to the central region does. We
show that CETP interacts with HDL, but not with LDL. Our findings demonstrate that a ternary tunnel
complex is not the mechanistic prerequisite to transfer CE among lipoproteins.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atherosclerotic plaques are a pathological hallmark of cardio-
vascular disease (CVD). Their formation is promoted by the accu-
mulation of fatty material, such as cholesterol and triglyceride, in
the arterial wall. Cholesterols are poorly water-soluble and are
transported in the blood stream by different classes of lipoproteins
for delivery to specific tissues: High density lipoproteins (HDLs)contain apolipoprotein A1 (apoA1) as their major protein compo-
nent, and carry their cholesteryl ester (CE) cargo from peripheral
tissues to the liver, where it is either metabolized or re-secreted.
Low density lipoproteins (LDLs) and very low density lipoproteins
(VLDLs) contain a single copy of apolipoprotein B (apoB), and
transport CEs to tissues expressing LDL receptors. CE-rich, oxidized
LDLs substantially contribute to plaque formation.
The concentration and distribution of CE in the different
lipoprotein classes and among HDL subclasses, depends on the
activity of the cholesteryl ester transfer protein (CETP) (Charles
and Kane, 2012). In the case of HDL, homotypic transfer of CE by
CETP leads to HDL remodeling and the formation of subparticles
of various sizes. CETP also mediates heterotypic CE transfer, e.g.,
from HDL to lipoprotein classes that contain apoB, such as LDL
and VLDL (Lagrost et al., 1990; Niesor et al., 2010; Rye et al.,
1999). CETP is a potential therapeutic drug target, since its inhibi-
tion increases the levels of both HDL-cholesterol and apoA1, which
have been shown in numerous epidemiological studies to correlate
with decreased CVD risk.
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did not benefit CVD patients in a large-scale clinical trial, and
was associated with major side effects (Barter et al., 2007), the
CETP modulator dalcetrapib (Niesor et al., 2010) was recently
found to decrease the risk of CVD in a subgroup of patients with
identified single nucleotide polymorphism in the ADCY9 gene
(Tardif et al., 2015). In addition, dalcetrapib, but not anacetrapib,
was found to increase apoA1-mediated antioxidant uptake in sev-
eral degenerative diseases, which is potentially protective (Niesor
et al., 2014). Two compounds chemically and mechanistically
related to torcetrapib, but without its side effects, are currently
under investigation in patients suffering from CVDs.
X-ray crystallography showed the 74 kDa protein CETP to be a
banana-shaped molecule with a pseudo twofold symmetry: a cen-
trally located N-terminus leads to a b-sheet rich barrel at one tip
(here designated N-terminal tip), which is connected via a central
domain to a similar, b-sheet rich barrel at the other tip (here des-
ignated C-terminal tip), and the fold concludes with a centrally
located a-helix at the C-terminus (Qiu et al., 2007). The size and
curvature of CETP match those of a discoid HDL particle. Conse-
quently, the concave CETP face was proposed to interact with
HDL (Qiu et al., 2007). However, the Ren group recently claimed
that CETP may interact with HDL via one of its distal ends
(Zhang et al., 2012). Three decades ago, Barter et al. suggested a
shuttle lipid-transfer mechanism in which CETP interacts with
HDL and is loaded with CE. The cargo would then be shuttled
and released by docking of CETP to LDL or VLDL (Barter et al.,
1982). According to this shuttle-model, CE molecules would be
transported and released one by one, in exchange for neutral lipids
such as triglycerides. The model is supported by kinetic studies
(Barter and Jones, 1980; Connolly et al., 1996). An alternative
model, also based on kinetics, suggests the formation of intermedi-
ary CETP, HDL, and LDL collision complexes, and that this proposed
complex might be transient (Ihm et al., 1982). The Ren group used
transmission electron microscopy (TEM) to study physical mix-
tures of CETP, HDL and LDL, and concluded that the N-terminal
tip domain of CETP binds to HDL and the C-terminal tip to LDL
(Zhang et al., 2012). Their study suggests the formation of a tran-
sient and/or stationary ternary tunnel complex between CETP,
HDL, and LDL or VLDL, where CETP bridges between the two
lipoprotein cores to allow transfer of lipid through its inner
hydrophobic tunnel. This model implies that CE transfer requires
the interaction of one tip of CETP with lipoproteins for efficient
CE transfer and, thus, that any disturbance of the interaction of
CETP tips with lipoproteins should interfere with CE transfer.
However, a couple of studies have shown that the carboxyl-
terminal a-helix of CETP, which is located in the middle of the con-
cave CETP face (Qiu et al., 2007), is involved in lipid transfer: Small
peptides restricted to, and derived from, this C-terminal a-helical
domain are amphipathic and capable of remodeling lipid mixtures
through secondary structure disorder-to-order transitions (Garcia-
Gonzalez et al., 2014). A few earlier studies suggested that the
carboxyl-terminal a-helix might impact CETP activity, and a series
of monoclonal antibodies binding near this region were shown to
be inhibitory (Guyard-Dangremont et al., 1999; Swenson et al.,
1989; Wang et al., 1992). Atomistic simulations related with to
inhibitory action of anacetrapib, suggested the importance of the
concave CETP face and the carboxyl-terminal a-helix for CETP
activity (Aijanen et al., 2014). Morton and Izem recently demon-
strated that CETP is involved in unidirectional lipid transfer with-
out the exchange of neutral lipids (Morton and Izem, 2014).
We have investigated HDL, LDL, CETP and their mixtures by
immuno-TEM and biophysical methods, and find that monoclonal
antibodies (mAb) directed against either the N or the C terminal tip
of CETP do not interfere with the formation of CETP–HDL com-
plexes, and do not interfere with the efficiency of CE transferbetween HDL and LDL particles. We also find that the binding of
CETP to HDL results in a variety of different CETP–HDL complexes;
CETP can bind to HDL via the N-terminal or the C-terminal tip
domain. Our results further indicate that the formation of ternary
HDL–CETP–LDL tunnel complexes is not a prerequisite for CE trans-
fer, in contradiction to the findings of Zhang et al. (2012).2. Materials and methods
2.1. Lipoprotein source and preparation protocol
Human LDL and human HDL preparations in 0.15 M NaCl, 0.01%
EDTA, pH 7.2 from normolipidemic blood plasma were purchased
from Intracel (MD, USA). Discoidal HDL particles were reconsti-
tuted (HDL) by the cholate dialysis method as described previously
(Ohnsorg et al., 2011). The HDL and LDL used for the AUC experi-
ments was purified from human plasma by density gradient ultra-
centrifugation (Intracel product information), which allows strong
enrichment, but not a quantitative separation of very low-density
lipoprotein (VLDL) (density < 1.019 g/ml), LDL (density = 1.019–
1.063 g/ml) and HDL (density = 1.063–1.21 g/ml).2.2. Preparation of CETP
A cell line, expressing recombinant human wild-type CETP, was
kindly provided by Professor Alan Tall (Columbia University)
(Weinberg et al., 1994). CETP was purified by hydrophobic interac-
tion chromatography and size exclusion chromatography (SEC)
according to Ohnishi et al. (1990) with modifications: After SEC
chromatography the buffer of the CETP-solution was changed to
20 mM HEPES/NaOH, 10% (w/v) glycerol, 0.02% sodium azide, pH
7.5. CETP was snap-frozen in this buffer and stored at 80 C.2.3. Generation of anti-CETP monoclonal Fab fragments
Monoclonal antibodies (mAb), mAb_6/2 and mAb_6/17, were
raised as described in Niesor et al. (2010). mAB_JHC1 was obtained
from Japan Tobacco as described by Takahashi et al. (2001). Fab
fragments were prepared from IgG using a Fab preparation kit from
Pierce (product code: 44980). The purity of all preparations was
confirmed by high-pressure liquid chromatography (HPLC) and
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–
PAGE). Fabs were in 20 mM HEPES/NaOH, 50 mM NaCl, pH 7.5.
They were snap-frozen and stored at 80 C.2.4. Analytical ultracentrifugation (AUC)
Sedimentation velocity datawere recorded at 20 Cusing a Beck-
man Coulter XLI analytical ultracentrifuge equipped with an Aviv
fluorescence detection system (Kingsbury and Laue, 2011). CETP
was labeled with Alexa Fluor 488 at a labeling degree of 0.8 mol/-
mol using the Alexa Fluor 488 antibody labeling kit (A20181,Molec-
ular Probes, Life Technologies), with the exception that Zeba spin
desalting columns (89882, 7 kDa MWCO, 0.5 ml, Thermo Scientific)
were used to removing excess free dye after labeling. To investigate
complex formation, 100 nM of Alexa Fluor 488-labeled CETP was
incubated with 0.5 mg/ml (protein content) of each human HDL
and/or LDL preparation, and centrifuged at 42,000 rpm (An60-Ti
rotor; 1.2 cm SedVel60 K centerpieces from Spin Analytical) with
fluorescence detection. Absorbance controls for lipoprotein peak
allocation were performed at 0.25 mg/ml (protein content) HDL or
LDL. Dulbecco’s Phosphate Buffered Saline (PBS) (Gibco) was used
as buffer in all AUC experiments. Data were analyzed with the pro-
grams Sedfit (Schuck, 2000) and Origin (OriginLab), and plotted
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MBR/software.html) and GraphPad Prism (GraphPad Software).
Due to the complexity of the samples containing HDL or LDL,
signal-weighted sedimentation coefficients, sw, of free CETP-
Alexa Fluor 488 were compared in the region of 3–4 S. The HDL
and LDL concentrations employed were adjusted according to the
protein content – LDL particles contain relatively more lipid and
also more sites for unspecific interaction with residual free Alexa
Fluor 488.
2.5. TEM sample preparation
2.5.1. Investigation of CETP–lipoprotein complex formation
Stock solutions of CETP (0.1 mg/ml) were mixed with pre-
diluted HDL (protein-content of the stock solution, 6.8 mg/ml) or
pre-diluted LDL (protein-content of the stock solution, 5 mg/ml)
at a weight to weight ratio of 5:1, respectively 2:3, and incubated
at 37 C (shaking) for 30 min. CETP/HDLmixtures containing CETP–
HDL complexes were mixed with LDL so that the final CETP/HDL/
LDL concentrations were 10 lg/ml/2 lg/ml (protein-content)/
15 lg/ml (protein-content), and similarly incubated. No additional
dilution was required for the TEM experiments.
2.5.2. Fab–CETP and Fab–Fab–CETP complex formation
Solutions of Fab (0.2 mg/ml) and CETP (0.1 mg/ml) were mixed
for 1 h at RT at a molar ratio of 2:1 to obtain Fab–CETP complexes,
and at a molar ratio of 1:1:0.5 to obtain Fab–Fab–CETP complexes.
The mixtures were diluted with PBS to a final protein concentra-
tion of 10 lg/ml immediately before TEM analysis.
2.5.3. Fab–CETP–HDL complex formation
Diluted mixtures (final concentration, 5 lg/ml Fab, 2.5 lg/ml
CETP) containing Fab–CETP complexes were mixed with diluted
solutions of HDL (protein content, 2.0 lg/ml) and incubated for
30 min at RT. No additional dilution was required for the TEM
experiments.
All pre-dilutions and dilutions for incubations and TEM analyses
were made with PBS, pH = 7.4 (Sigma).
2.6. Analysis by negative stain TEM
5 lL of sample solution was adsorbed for 1 min to glow dis-
charged, parlodion and carbon-film coated TEM grids. Excess sam-
ple was removed with blotting paper. The grid was washed 5 times
on milliQ water drops, negatively stained with 2% uranyl acetate,
blotted again, and air-dried. Images were recorded with a Philips
CM10 TEM (FEI Company, Eindhoven, The Netherlands) operated
at 80 kV, at a nominal magnification of 1300000, using a
2 K  2 K Veleta side-mounted TEM CCD Camera (Olympus), corre-
sponding to a pixel size of 3.8 Å at the specimen level.
2.7. Image processing
Images of 600 particles for HDL, 100 particles for LDL, 200 par-
ticles for the Fab–CETP complexes, and 200 particles for the Fab–
CETP–HDL complexes were selected manually using the BOXER
software (EMAN software package (Ludtke et al., 1999)), and win-
dowed. Particles were classified with the EMAN1 program startnr-
classes, requesting approximately 50 to 80 particles per class
average. Alignment and classification in EMAN1 generated several
classes per dataset.
Particle sizes were determined using the ImageJ software
(Rasband, 2015).
All visualization and 3D modeling was done using the UCSF Chi-
mera package (Pettersen et al., 2004). The models were prepared
by manually selecting the orientations of the three-dimensional(3D) atomic structures that correspond to two-dimensional (2D)
projections obtained by single particle analysis (projection match-
ing). Briefly, atomic structures of CETP (PDB code 2ODB) and an
individual Fab (obtained from PDB code 1IGY) were displayed in
Chimera as all atoms representations on a pale gray background.
Views obtained by rotation/translation then look similar to 2D pro-
jections and can, thus, be compared and aligned manually with the
TEM single particle class averages. Once the optimal orientation of
CETP and superimposed Fab was found, the respective atomic coor-
dinates were written out as PDB files. These PDB files were used to
produce electron density map surfaces at 20 Å resolution in EMAN
(Ludtke et al., 1999), using the command ‘‘pdb2mrc apix = 1 res = 20
center”. A general constraint was that the final model had to fit all
data sets documenting Fab binding to CETP (Figs. 1 and 2 and Sup-
plementary Figs. S2, S3, S5).
2.8. Heterotypic HDL-to-LDL transfer assay using 3H-labeled CE HDL
The inhibitory potency of mAb_6/2, mAb_6/17 and mAb_JHC1
to decrease CE transfer from HDL to LDL by CETP (Roy et al.,
1996), was measured using a scintillation proximity assay kit,
(#TRKQ7015; GE Healthcare, Waukesha, WI, USA). CE-labeled
HDL donor particles were incubated in the presence of purified
CETP protein (final concentration, 0.5 lg/ml) and biotinylated
LDL acceptor particles for 3 h at 37 C as described in Barter et al.
(Barter and Jones, 1980). Subsequently, streptavidin-coupled
polyvinyltoluene beads containing a liquid scintillation cocktail
binding selectively to biotinylated LDL were added. The amount
of CE transferred to LDL was measured by b counting.
2.9. Heterotypic transfer assay using fluorescently-labeled cholesteryl
ester liposomes
The fluorescence-based CETP activity assay kit was obtained
from ROAR Biomedical Inc. (New York, USA). The donor liposomes
contain CE labeled with the fluorophore NBD [N-(7-nitrobenz-2-o
xa-1.3-diazol-4-yl)] in a self-quenched condition (Swenson et al.).
These donor liposomes were then incubated with the liposomal
acceptor particles in the presence of CETP. CETP-mediated transfer
was recognized and determined by measuring the increase in the
fluorescence signal intensity. The intensity increases because, in
the acceptor particle, the fluorescent lipid is released from the
self-quenched donor state. The number of transferred CE mole-
cules is thereby directly proportional to the increase in the fluores-
cence signal. To measure the inhibitory potency of mAb_6/2,
mAb_6/17, mAb_JHC1, each mAb (final concentration, 100 lg/ml)
was incubated with CETP (final concentration, 30 lg/ml) for
10 min at RT. 10 lL of this incubate and 4 lL of the donor and
acceptor CE liposomal vesicles, were then added to 186 lL of assay
buffer. After incubating for 3 h at 37 C, the increase in fluores-
cence intensity was measured at an excitation wavelength of
465 nm and an emission wavelength of 535 nm (Tecan Microplate
Reader Infinite M200 Pro, Tecan, Maennedorf, Germany). A mouse
mAb raised against an irrelevant protein, glutathione
S-transferases (GST), was used as negative control (mAb control).
2.10. HDL remodeling assay
HDL was incubated with CETP (30 lg/ml) in the presence of
100 lg/ml mAb for 21 h at 37 C. After the incubation step, the
concentration of pre-b-HDL was determined by ELISA (Sekisui
Medical Co. Ltd, Tokyo, Japan). The CETP-dependent neutral lipid
transfer generated a subclass of HDL, the CE-poor particle known
as pre-b-HDL. The amount of pre-b-HDL was then quantified by
detecting the exposure of a specific epitope on the apoA1 present,
as described by Miida et al. (2003). A mouse mAb raised against an
Fig. 1. CETP and immunolabeled CETP imaged by negative stain TEM. (A) CETP. Right: Overview image; the white circles indicate individual CETP molecules. Left: A
representative single particle class average (top) and the correspondingly aligned and oriented 20 Å-resolution CETP model generated from the known crystal structure (PDB
code: 2OBD) (bottom). See also Supplementary Fig. S1. (B) Class averages (top) and corresponding models displayed as colored density map surfaces (bottom) showing single
and double immunolabeling of CETP by the indicated Fabs. See also Supplementary Figs. S2, S3. The proposed models were produced by manual projection matching as
described in Section 2. (C) The most probable binding sites for the three Fabs (compare Supplementary Fig. S2 and S3; see Section 2). A rainbow colored ribbon model of CETP
(PDB code: 2OBD) is displayed inside a gray transparent density map calculated at 20 Å resolution; the view shows the concave CETP face. Fab fragments (PDB codes 1IGY) are
represented as colored opaque density map surfaces at 20 Å resolution. The C-terminal a-helix of CETP is located approximately at the binding site of Fab_JHC1. The often
specific and defined angle made by the Fab to the longitudinal CETP axis when adsorbed to the carbon film, served as a guideline for model construction. The double labeling
experiments confirmed these angles and showed the relative orientations of the two Fabs. The end assignments are tentative as the epitopes to which the Fabs bind are not
known from other methods and the resolution of negative stain TEM does not allow the two ends of the CETP molecule to be distinguished with certainty. This model and all
partial models are shown purely as illustrations to aid understanding; the ends to which the Fabs bind are, thus, intentionally not specified. Scale bar: (A) 50 nm; all inset
boxes are 30 nm by 30 nm.
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control).
2.11. Binding characterization by SPR spectroscopy
SPR experiments were performed using a capture assay method
to determine mAb–protein interactions and binding affinities
(Biacore Instruments). Goat anti-mouse mAbs were covalently
immobilized on the sensor chip surface by amine coupling. The
antibodies mAb_6/2, mAb_6/17 and mAb_JHC1, were then cap-
tured for the binding assay (ca. 150–300 RU of captured antibody).
Subsequently, different CETP concentrations were injected and
passed over the chip surface at a flow rate of 50 lL/min. Surface
regeneration with 100 mM phosphoric acid was performed after
each injection. The experiments were carried out at 25 C using a
5 mM Hepes pH 7.5, 50 mM NaCl, 5% glycerol, 0.01% P20 running
buffer.
3. Results
Analysis of recombinant human CETP by negative stain TEM
confirmed the banana-like shape of the protein (Figs. 1A and S1)
(Qiu et al., 2007). At the 20 Å resolution achievable by this method,
the two halves of the 13-nm-long, curved structure look similar.
Immunolabeling was used to locate specific CETP domains. The
required precision was attained by using the fragment antigen-
binding regions (Fabs; Supplementary Fig. S2) of monoclonal anti-
bodies (mAbs) against CETP; Fabs bind to target proteins by the
same, well-defined interaction as the full mAbs, but the stiff struc-tures of the smaller Fabs allow image processing, while the more
flexible full-length antibodies do not (Wu et al., 2012). Impor-
tantly, as in full-length antibodies, the characteristic projections
of Fabs that lie flat or almost flat on the support film (Supplemen-
tary Fig. S1B) allow them to be unambiguously identified by nega-
tive stain TEM. It is known from studies using ELISA, that each of
the three mAbs employed, mAb_6/2, mAb_6/17 and mAb_JHC1,
binds to and masks a different epitope on the CETP surface
(Niesor et al., 2010). Surface plasmon resonance (SPR) spec-
troscopy used to determine the dissociation constants (KD) of
mAb/CETP complexes showed that mAb_JHC1 has the lowest affin-
ity of the three: KD of mAb_6/2 = 0.001 nM, KD of
mAb_6/17 = 0.7 nM and KD of mAb_JHC1 = 40 nM. TEM images of
negatively stained CETP labeled by Fab_6/2 (from mAb_6/2) and
Fab_6/17 (from mAb_6/17) alone (Figs. 1B,C and S2A,B) and in
combination (Supplementary Fig. S3A), confirm that the two Fabs
bind at different epitopes (Niesor et al., 2010) and show these to
be at opposite tips of the CETP molecule. Similar TEM experiments
showed that Fab_JHC1 (from mAb_JHC1) binds to the concave sur-
face (Figs. 1B,C and S2C), closer to the binding site of Fab_6/2 than
to the binding site of Fab_6/17 (Figs. 1B,C and S3B,C).
As shown by both analytical ultracentrifugation (AUC; Fig. 2)
and TEM (Fig. 3), CETP-HDL complexes formed when CETP was
mixed with HDL as indicated in Section 2. In the TEM images, the
circular projections typical of HDL (Supplementary Fig. S4A) are
frequently extended by an elongated protrusion with the shape
of CETP but usually one third shorter (Figs. 3A and S4B). The overall
shapes of CETP, HDL, and the CETP–HDL complexes agree with
those reported by Zhang et al. (2012). Multiple CETP binding
Fig. 2. Normalized sedimentation coefficient distributions c(s) determined by
analytical ultracentrifugation (AUC). (A) The sedimentation of 100 nM CETP labeled
with Alexa Fluor 488 followed by fluorescence detection, carried out in the absence
and presence of HDL, LDL or an HDL/LDL mixture (0.5 mg/ml protein each). CETP
readily formed a complex with HDL (peak at 4.6 S) but not with LDL; the total
fluorescence signal/quantum yield of CETP-Alexa Fluor 488 was markedly increased
in the presence of LDL compared to HDL. The sedimentation of the HDL–CETP
complex is dominated by the HDL particle, addition of more than one CETP to HDL is
not expected to markedly change the sedimentation coefficient, consequently
the stoichiometry of the HDL–CETP complex(es) cannot be inferred from the data.
The signal-weighted sedimentation coefficients, sw, of free CETP-Alexa Fluor 488 in
the 3–4 S region are the same for all samples. Inset: AUC control experiment. This
was performed with 10 nM Alexa Fluor 488 in presence of either HDL or LDL
(0.5 mg/ml protein each). The profiles show that residual free Alexa Fluor 488 stains
both HDL and LDL, which explains the occurrence of the minor peaks at 6–7 S in the
main graph. (B) AUC control experiment. Sedimentation of 0.25 mg/ml HDL or LDL
in the absence of CETP detected by the absorbance at 280 nm. The upper panels of
(A) and (B) show the integrated distributions (total loading signals.)
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binding to the same HDL particle ((Zhang et al., 2012), and Figs 3A
and S4B). Neither ternary HDL–CETP–HDL complexes nor higher
stoichiometries were observed (Supplementary Fig. S4B). Occa-
sionally, a second HDL was observed in close proximity to an
HDL–CEPT complex, and very rarely HDL–CETP clusters were seen,
as always expected due to adsorption artifacts. Pure HDL–CETP
complexes were repeatedly observed on negatively stained TEM
grids (considered further below).
To further investigate how CETP interacts with HDL, HDL was
incubated with solutions containing Fab_6/2–CETP, Fab_6/17–
CETP, or Fab_JHC1–CETP complexes, and inspected by negative
stain TEM. Many labeled CETP–HDL complexes were visible in
samples containing Fab_6/2 or Fab_6/17 and most of these parti-
cles had a similar shape, allowing statistical analysis by image
processing in both cases (Figs. 3B,C and S5A,B). Surprisingly, the
data reveal that CETP is able to bind HDL via either its N- orC-terminal tip. The CETP–HDL complexes were less frequently
labeled by Fab_JHC1, prohibiting statistically meaningful image
processing. Nevertheless, when labeling was evident, the Fab_JHC1
was directly adjacent to the HDL particle (Figs. 3 and S5C).
To investigate the potential interaction of CETP with LDL
(Fig. 4A), mixtures of CETP and LDL were prepared as above and
analyzed by AUC and negative stain TEM. According to the AUC
data, significant complex formation was observed for CETP in the
presence of HDL, but not in the presence of LDL (Fig. 2). A control
experiment demonstrated that the free Alexa Fluor 488 dye could
interact with HDL and LDL particles (Fig. 2A, inset). The CETP-Alexa
Fluor 488 inevitably contained residual free dye. Thus, the very
minor peaks at 6–7 S (on average 4.2% of total signal) in the sedi-
mentation coefficient distributions shown in Fig. 2A cannot be
attributed to complexes consisting of CETP and LDL, but are rather
due to unspecific interaction of residual free dye with LDL. In
agreement, only randomly distributed free CETP particles and free
LDL particles were found on the TEM grids; CETP–LDL complexes
were not detected (Fig. 4B). This observation contradicts the report
by the Ren group from 2012 (Zhang et al., 2012). Further, physi-
cally stable ternary complexes of HDL–CETP–LDL were not
detected by AUC (Fig. 2) when a mixture of CETP and HDL com-
plexes was incubated at room temperature with LDL. On corre-
sponding TEM grids, HDL was occasionally in very close
proximity to LDL (Fig. 4C). At first sight, these aggregates could
be interpreted as ternary complexes. However, a simulation of
the adsorption process occurring when grids are prepared for neg-
ative stain TEM from heterogeneous HDL/CETP/LDL samples gener-
ated the same forms (Supplementary Fig. S6), clearly indicating
that the apparent complexes are most likely adsorption artefacts.
This conclusion differs from that of Zhang et al. (2012). The forma-
tion of CETP–HDL complexes and the absence of CETP–LDL and
HDL–CETP–LDL documented by the above data (Figs. 2 and 4)
implies that any interaction that CETP might have with LDL is tran-
sient as suggested by Morton and Greene (2003), and does not
result in the formation of a stable isolatable complex.
Inhibition of neutral lipid transfer by mAb_6/2, mAb_6/17 and
mAb_JHC1, which correspond to Fab_6/2, Fab_6/17 and Fab_JHC1
used for TEM immunolabeling, was studied in three different and
independent assays (Table 1). These were a heterotypic HDL-to-
LDL transfer assay that determined the transfer of radiolabeled
CE from HDL to LDL (Fig. 5A), a heterotypic vesicle-based transfer
assay that measured the transfer of a fluorescent CE analog from
donor to acceptor phospholipid vesicles (Fig. 5B), and a homotypic
HDL-to-HDL transfer assay that measured CETP-dependent HDL
remodeling by incubating HDL with CETP and quantifying the
generation of pre-b-HDL using a specific ELISA procedure
(Fig. 5C). Surprisingly, in all three assays, the monoclonal antibod-
ies mAb_6/2 and mAb_6/17, which bind to the tip-regions of CETP
(Figs. 1B,C and S2A,B), had no detectable effect on lipid transfer. In
contrast, inhibition of lipid transfer was observed with mAb_JHC1,
which binds to an epitope close to the center of the concave CETP
face near the a-helical C-terminus (Figs. 1B,C and S2C). The com-
paratively high KD of mAb_JHC1 of 40 nM makes the inhibition
observed with this mAb even more striking.4. Discussion
The main results can be summarized as follows: (i) a significant
amount of ternary HDL–CETP–LDL complexes was not detected by
AUC, (ii) mAbs binding to epitopes in the tip region of CETP that
were expected to hinder the formation of the HDL–CETP–LDL tern-
ary tunnel complexes, had poor CETP inhibitory potency, and (iii)
according to both the AUC and TEM data, CETP preferentially inter-
acts with HDL. Indeed, TEM indicated that multi-stoichiometric
Fig. 3. CETP–HDL complexes and their immunolabeling. Either unlabeled CETP or preformed Fab–CETP complexes were incubated with HDL at 37 C. The mixture was then
imaged by negative stain TEM. (A) CETP–HDL. (B) (Fab_6/2–CETP)–HDL. (C) (Fab_6/17–CETP)–HDL. (D) (Fab_JHC1–CETP)–HDL. Top row: (A–C), representative class averages
generated by single particle analysis, (D) single raw image. Bottom row, (A) single raw images showing single and multiple binding of CETP to HDL particles, (B,C) models
corresponding to the above averages, rendered as colored density map surfaces at a resolution of 20 Å; the circular HDL projections have diameters of 16–18 nm and about
one third of the CETP molecules are attached to them. The large boxes are 38 by 38 nm and the small boxes in (A) 48 by 48 nm.
Fig. 4. Interaction of CETP with HDL, LDL and HDL/LDL mixtures studied by TEM. (A) Overview of a 500 times diluted LDL stock solution (5 mg/ml) and 2 representative class
averages, each containing 30 particles (left), and overview of a 5000 times diluted HDL stock solution (7.4 mg/ml) and 8 representative class averages, each containing 50
particles (right); for comparison with (B) and (C). The average LDL diameter ranged from 38 to 42 nm and the average HDL diameter from 16 to 18 nm. Thus, LDL and HDL can
easily be distinguished in mixed samples. (B) CETP and LDL; CETP–LDL complexes were not detected. Unbound individual CETP molecules are visible in the background
(arrows). (C) CETP–HDL and LDL. The CETP–HDL complexes are clearly visible (arrows) and some HDL and LDL particles are close to one another or even in contact, giving the
impression that they might be ternary CETP–HDL–LDL complexes. However, a simulation shows that this apparent association is most probably an adsorption artifact; see
Supplementary Fig. S6. Scale bars: 60 nm; inset boxes are 48 by 48 nm (left) and 24 by 24 nm (right).
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Table 1
Summary of the neutral lipid transfer inhibitory potency of mAbs_6/2, mAb_6/17 and mAb_JHC1, which correspond to the Fabs used in the TEM immunolabeling experiments.
Binding site on CETP Heterotypic transfer
(3H-CE-labeled HDL assay)
Heterotypic transfer
(NBD-CE-labeled liposomes assay)
Homotypic transfer
(HDL remodeling assay)
mAb_6/2 Tip region No effect No effect No effect
mAb_6/17 Opposite tip region No effect No effect No effect
mAb_JHC-1 Middle of concave side Inhibition Inhibition Inhibition
M.E. Lauer et al. / Journal of Structural Biology 194 (2016) 191–198 197assemblies of CETP with HDL are possible, but did not reveal CETP–
LDL complexes. Moreover, there was no evidence that CETP binds
to HDL exclusively by either its N- or its C-terminal tip. Antibody
fragments Fab_6/2 and Fab_6/17 label opposite ends of the struc-
ture, as shown by double immunolabeling of CETP, and, in agree-
ment with the corresponding mAb experiments, neither Fab
prevented the interaction of CETP with HDL particles. The forma-Fig. 5. Neutral lipid transfer inhibitory potency of mAbs_6/2, mAb_6/17 and
mAb_JHC1, which correspond to the Fabs used for TEM labeling. (A) Heterotypic
transfer of radiolabeled CE from HDL to LDL. (B) Heterotypic transfer of fluorescent
CE from donor to acceptor liposomal vesicles. (C) Remodeling of HDL and the
formation of pre-b HDL during homotypic transfer. Only the monoclonal antibody
mAB_JHC1 shows significant inhibitory potency.tion of CETP–HDL complexes and the lack of significant amounts
of CETP–LDL (Figs. 2 and 4B) and HDL–CETP–LDL complexes
(Fig. 2), is supported by size exclusion chromatography; CETP
elutes in the HDL peak and in the apolipoprotein-free peak, but
is not present in the LDL or the VLDL peak (Dernick et al., 2011).
From this and the new TEM results reported above, we conclude
that an interaction of CETP with LDL can only be transient at best
(Morton and Greene, 2003). These TEM results were unexpected.
Together, they indicate that the inhibition of a ternary HDL–
CETP–LDL tunnel complex may not be an efficient strategy to sup-
press CETP-mediated heterotypic lipid transfer.
Homotypic transfer (HDL remodeling) due to interaction of
CETP with HDL is likely to be a necessary step, even for heterotypic
lipid exchange. This is suggested by two findings. (i) Complexes of
CETP–HDL are observed in the absence and presence of LDL. (ii)
The inhibitory potencies of mAb_6/2, mAb_6/17 and mAb_JHC1
on HDL remodeling, and in the complete absence of LDL, directly
correlate to their effect on heterotypic transfer; in both cases
mAb_JHC1 inhibits transfer, but mAb_6/2 and mAb_6/17 do not.
LDL particles could therefore be seen as lipid reservoirs competing
with the distribution of lipids among different HDL subclasses. In
this model, the presence of LDL would scavenge CE and other lipids
from HDL and promote the release of apoA1 (Liang et al., 1994).
The unexpected ability of CETP to bind to HDL via either its N- or
C-terminal tip introduces dissimilarity into otherwise comparably
structured CETP–HDL particles. Such differently structured com-
plexes might have slightly different binding properties. Intrigu-
ingly, ternary HDL–CETP–HDL complexes were not detected, even
though multiple copies of CETP can interact with a single HDL par-
ticle (Figs. 3A and S4B). The size, stability, and structure of HDL is
known to depend to a large extent on its cholesterol content, imply-
ing that any transfer of CE and lipids stabilizes or destabilizes differ-
ent forms of HDL and/or CETP–HDL complexes (Auton et al., 2013).
As short-lived transient complexes in such heterogeneous, dynamic
and complex mixtures are difficult to detect by any analytical
method, the possible transient and mechanistic scenarios remain
a matter of speculation. However, it is a broadly accepted concept
that the physical stability of lipid particles and membranes is gen-
erally balanced by the adhesion of proteins or amphipathic pep-
tides, and that a change in the particle surface/volume ratio is a
general trigger of lipid remodeling processes (McMahon and
Gallop, 2005). In principle, such a mode of action might already
be sufficient to explain the transfer of lipids from one lipoprotein
complex to another. To a certain degree, this is supported by the
fact that small-molecule peptides derived from the C-terminal
a-helix of CETP are amphipathic and – like CETP – capable of
remodeling lipid mixtures (Garcia-Gonzalez et al., 2014). Further,
molecules and antibodies that bind near the C-terminal a-helix of
CETP, interfere with CE transfer (Maugeais et al., 2013; Swenson
et al., 1989; Wang et al., 1992). In agreement, the inhibiting anti-
body employed in the presented study, mAb_JHC1, binds near this
a-helix on the central concavely-curved region of CETP.5. Conclusions
The static TEM data, and the lipid transfer efficiencies of CETP in
the presence of inhibiting and non-inhibiting mAbs, do not allow
198 M.E. Lauer et al. / Journal of Structural Biology 194 (2016) 191–198conclusions to be drawn about the transient states mechanistically
required to transfer CE between lipoproteins: a shuttle mechanism
or even a transient short-lived ternary collision complex, which
can involve differently constituted and destabilized forms of HDL,
HDL–CETP and LDL, are possible (Barter and Jones, 1980; Barter
et al., 1982; Connolly et al., 1996; Ihm et al., 1982). However, our
data show that the impact of ternary tunnel complexes (HDL–
CETP–LDL), if they are formed at all, must be minor. The functional
impact of the N- or C-terminal CETP tip domains protruding from
CETP–HDL complexes appears to be secondary in the sense that
mAbs targeting them neither interfere with the homotypic nor
with the heterotypic transfer activity of CETP. This is corroborated
by the fact that we could not document the formation of stable
HDL–CETP–LDL and HDL–CETP–HDL complexes. The monoclonal
antibodies described here, mAb_6/2, mAb_6/17, and mAb_JHC-1,
are powerful tools to further unravel the highly dynamic and com-
plex binding scenario underlying CETP-mediated transfer of CE
among lipoproteins.
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